API | navitoclax

navitoclax Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Navitoclax is an experimental orally active anti-cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. ^Wikipedia

Chemistry

SMILES: CC1(C)CCC(=C(CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc6ccccc6)c(c4)S(=O)(=O)C(F)(F)F)C1)c7ccc(Cl)cc7
InChIKey: JLYAXFNOILIKPP-KXQOOQHDSA-N
Mol. Mass: 974.63
ALogP: 8.83 Partition coefficient
ChEMBL Molecule:
navitoclax

More Chemistry

Pharmacology

Mechanisms of Action:
- Apoptosis regulator Bcl-2 (Homo sapiens) ^UniProt
- Bcl-2-like protein 2 (Homo sapiens) ^UniProt
- Bcl-2-like protein 1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

abt263 | abt 263 | abt-263 | navitoclax

Organizations (23)

Research & Development (23)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (25)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (25)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Fibrosis (Phase 1)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1)

Hepatitis B (Phase 1)

Hepatitis C, Chronic (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Melanoma (Phase 1/Phase 2)

Myeloproliferative Disorders (Phase 1)

Neoplasms (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Primary Myelofibrosis (Phase 3)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 41
# of Trial Organizations: 23

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue